Allschwil, Switzerland

Time filter

Source Type

The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R^(1 )and R^(2 )are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D_(2 )receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.


Patent
Actelion Pharmaceuticals | Date: 2015-03-23

The invention relates to compounds of Formula (I) wherein R^(1), R^(2), R^(3), R^(4 )and R^(5 )are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.


The invention relates to antibacterial compounds of formula I


Patent
Actelion Pharmaceuticals | Date: 2015-06-02

The invention relates to compounds of formula (I) wherein X, Y, R^(1), R^(2), (R^(4))_(n), and (R^(5))_(m )are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.


The present invention relates to azaindole acetic acid derivatives of formula (I), wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.


The present invention relates to azaindole acetic acid derivatives of formula (I), (I) wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.


The invention relates to antibacterial compounds of formula (I), wherein R1 is one of the groups represented below (AA), wherein A is a bond, CH=CH or CC; U is N or CH; V is N or CH; W represents N or CH; and R1A, R2A, R3A, R1B and R1C are as defined in the claims; and salts thereof.


Patent
Actelion Pharmaceuticals | Date: 2017-03-22

The invention relates to antibacterial compounds of formula I, wherein R1 is H or halogen; R2 is the group M; R3 is H or halogen; M is MA or MB wherein A is a bond or CC; R1A is H or halogen; R2A is H, alkoxy or halogen; R3A is H, alkoxy, hydroxyalkoxy, hydroxyalkyl, 1,2-dihydroxyethyl, dialkylamino, 1-hydroxymethyl-cycloprop-1-yl, 1-((dimethylglycyl)oxy)methyl-cycloprop-1-yl, 3-hydroxyoxetan-3-yl, morpholin-4-ylalkyl or morpholin-4-ylalkoxy; and R1B is a group as defined in claim 1; and salts thereof.


Patent
Actelion Pharmaceuticals | Date: 2017-02-01

The invention relates to compounds of Formula (I) wherein R1, R2, R3, R4 and R5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.


Patent
Actelion Pharmaceuticals | Date: 2017-04-12

The invention relates to compounds of formula (I) Formula (I) wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.

Loading Actelion Pharmaceuticals collaborators
Loading Actelion Pharmaceuticals collaborators